Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-745 in mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease
2014-002855-25Phase 2Completed
- Sponsor
- CervoMed
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of neflamapimod in Alzheimer's disease (AD) (2 arms), sponsored by CervoMed. Primary endpoint: Change in quantitative relative cortical uptake of 11C-PiB. Started Nov 2014; status: completed.
02
Drugs
neflamapimod
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2014-002855-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002855-25.